Clinical trial NCT01847352: Iron Status and Hypoxic Pulmonary Vascular Responses
Official title: Effect of Endogenous Iron Status on Hypoxic Pulmonary Vascular Responses and Their Attenuation by Intravenous Iron
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lung Hypoxia
Pulmonary Arterial Hypertension
Iron Deficiency
Keywords: Hypoxia
Pulmonary hypertension
Iron deficiency
Hypoxic pulmonary vasoconstriction
Lead sponsor: University of Oxford
Sponsor class: OTHER
Collaborators: name: National Institute for Health Research, United Kingdom
name: British Heart Foundation
First posted: 2013-05-06
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: On exposure to hypoxia (low oxygen) the normal response is for pulmonary arterial systolic blood pressure (PASP, blood pressure through the lungs) to increase. We have previously shown that raising iron by giving an infusion of iron into a vein reduces this pressure rise and that lowering iron by giving a drug that binds iron, magnifies this response. This is potentially a clinically important observation since iron-deficient people may be at increased risk of pulmonary hypertension if exposed transiently or permanently to hypoxia due to lung disease or residence at high altitude; furthermore if this were true then intravenous iron could be an important treatment in this patient group in the event of hypoxic exposure. The observed effects of iron on PASP are likely to be because iron levels affect oxygen sensing. Low iron levels make the body behave as if exposed to low oxygen by inhibiting the breakdown of the family of oxygen-sensing transcription factors, 'hypoxia inducible factor' or HIF. This includes one of the body's normal responses to low oxygen levels - raising blood pressure through the lungs.

This study will answer the question (1) do iron-deficient volunteers have a greater rise in PASP with hypoxia than those who are iron-replete, and (2) does giving intravenous iron cause a greater reduction in the rise in PASP in those who are iron-deficient than iron-replete? The purpose of this study is not to test the safety or clinical efficacy of iron which is already known.


Eligibility criteria: Inclusion Criteria:

* Willing and able to give informed consent for participation in the study
* Men and women aged 18 years or older and generally in good health
* Detectable tricuspid regurgitation on echocardiography during both normoxia and hypoxia enabling measurement of pulmonary arterial pressure
* For iron-deficient volunteers: ferritin ≤15microg/L and transferrin saturation \<16%
* For iron-replete volunteers: ferritin ≥20microg/L and transferrin saturation ≥20%

Exclusion Criteria:

* Haemoglobin \<8.0g/dl
* Haemoglobinopathy
* Iron overload defined as ferritin \>300microg/L
* Hypoxia at rest or on walking (SaO2 \<94%) or significant comorbidity that may affect haematinics, pulmonary vascular or ventilatory responses, e.g. current infection, a chronic inflammatory condition, known cardiovalvular lesion or pulmonary hypertension, uncontrolled asthma or chronic obstructive pulmonary disease
* Exposure to high altitude (\>2,500m) within the previous six weeks or air travel \>4 hours within the previous week
* Iron supplementation or blood transfusion within the previous 6 weeks
* Pregnancy or breast feeding

Primary outcomes:
measure: ∆PASP in iron-replete compared to iron-deficient volunteers
timeFrame: During six hours of hypoxia without prior iron infusion
Secondary outcomes:
measure: ∆PASP, with versus without prior iron infusion, in iron-replete compared to iron-deficient volunteers
timeFrame: During two six-hour periods of hypoxia; assessments separated by at least a week
measure: Blood parameter changes, pre- versus post-intravenous iron, in iron-replete compared to iron-deficient volunteers
timeFrame: After six hours of hypoxia, at both study assessments
measure: Ventilation parameter changes, pre- versus post-intravenous iron, in iron-replete compared to iron-deficient volunteers
timeFrame: During six hours of hypoxia, at both study assessments
Other outcomes:
measure: Fatigue scores in iron-replete versus iron-deficient volunteers
timeFrame: Assessed at baseline visit
Locations:
city: Oxford
country: United Kingdom
facility: University of Oxford Department of Physiology, Anatomy and Genetics
state: Oxfordshire
Study officials:
affiliation: University of Oxford
name: Annabel H Nickol, MBBS PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Smith TG, Balanos GM, Croft QP, Talbot NP, Dorrington KL, Ratcliffe PJ, Robbins PA. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol. 2008 Dec 15;586(24):5999-6005. doi: 10.1113/jphysiol.2008.160960. Epub 2008 Oct 27.
citation: Smith TG, Talbot NP, Privat C, Rivera-Ch M, Nickol AH, Ratcliffe PJ, Dorrington KL, Leon-Velarde F, Robbins PA. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA. 2009 Oct 7;302(13):1444-50. doi: 10.1001/jama.2009.1404.
citation: Talbot NP, Smith TG, Privat C, Nickol AH, Rivera-Ch M, Leon-Velarde F, Dorrington KL, Robbins PA. Intravenous iron supplementation may protect against acute mountain sickness: a randomized, double-blinded, placebo-controlled trial. High Alt Med Biol. 2011 Fall;12(3):265-9. doi: 10.1089/ham.2011.1005.
citation: Balanos GM, Dorrington KL, Robbins PA. Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1. J Appl Physiol (1985). 2002 Jun;92(6):2501-7. doi: 10.1152/japplphysiol.00965.2001.
citation: Frise MC, Cheng HY, Nickol AH, Curtis MK, Pollard KA, Roberts DJ, Ratcliffe PJ, Dorrington KL, Robbins PA. Clinical iron deficiency disturbs normal human responses to hypoxia. J Clin Invest. 2016 Jun 1;126(6):2139-50. doi: 10.1172/JCI85715. Epub 2016 May 3.